Boston Scientific has launched its WallFlex Biliary Transhepatic Stent System for treatment of biliary strictures arising from malignant tumors.
The device will be available in the U.S. and international markets, and the WallFlex Biliary Transhepatic Fully Covered Stent System is available in countries complying with the CE marking for treatment of benign biliary strictures.
“We are very excited that the WallFlex Stent technology, originally designed for gastroenterologists, is now available for interventional radiologists and the patients we typically treat through percutaneous procedures,” said Kelvin Hong, M.D., Johns Hopkins University, Baltimore, Maryland. “The WallFlex Biliary Transhepatic Stent System offers the latest advances in self-expanding metal stent technology with a delivery system designed specifically for the interventional treatment of malignant biliary strictures.”
The WallFlex Biliary Transhepatic Stent is available in fully covered, partially covered and uncovered versions in multiple sizes to accommodate different anatomical and clinical requirements. The covered stents have a silicone polymer Permalume® coating designed to reduce the potential for tumor/tissue ingrowth, and an integrated retrieval loop for endoscopic removal or repositioning during the initial procedure in patients that may have an ERCP performed.
The WallFlex Biliary RX Stents and the WallFlex Biliary Transhepatic Stents are CE-Marked and have received FDA clearance for the palliative treatment of malignant biliary strictures. Additionally, the WallFlex Biliary RX Fully Covered Stent and the WallFlex Biliary Transhepatic Fully Covered Stent System are CE-Marked for the treatment of benign biliary strictures.